People · Operator

Todd Schwarzinger

Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology

1
Companies
2
Filings
$71.8M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Centerline Biomedical, Inc.BiotechnologySeries B$71.8M$55.1M2022
Operator network

Todd Schwarzinger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Akhil Saklecha · 3 companies · 1 sharedAkhil SaklechaKaren Shanahan · 3 companies · 1 sharedKaren ShanahanJai N. Gupta · 2 companies · 1 sharedJai N. GuptaMichael Whitman · 2 companies · 1 sharedMichael WhitmanArnaud Marie · 1 companies · 1 sharedArnaud MarieGulam Khan · 1 companies · 1 sharedGulam KhanIndrani Egleston · 1 companies · 1 sharedIndrani EglestonJim N. Zalar · 1 companies · 1 sharedJim N. ZalarJim Zalar · 1 companies · 1 sharedJim ZalarMitch Wolf · 1 companies · 1 sharedMitch WolfPhil N. Rackliffe · 1 companies · 1 sharedPhil N. RackliffePhil Rackliffe · 1 companies · 1 sharedPhil RackliffeVikash K. Goel · 1 companies · 1 sharedVikash K. GoelVikash N. Goel · 1 companies · 1 sharedVikash N. GoelVinod K. Goel · 1 companies · 1 sharedVinod K. GoelCenterline Biomedical, Inc. · $71.8M raisedCenterline Biomedical…Todd SchwarzingerTS
Todd Schwarzinger Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Todd Schwarzinger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Akhil Saklecha13
Karen Shanahan13
Michael Whitman12
Jai N. Gupta12
Indrani Egleston11
Vikash K. Goel11
Vinod K. Goel11
Phil Rackliffe11
Phil N. Rackliffe11
Vikash N. Goel11
Jim Zalar11
Jim N. Zalar11
Mitch Wolf11
Gulam Khan11
Arnaud Marie11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.